ATARA BIOTHERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)

Item 1.01 Entry into a Material Definitive Agreement

As previously disclosed, on May 13, 2022, Atara Biotherapeutics, Inc. received written notice of termination from Bayer AG of... | August 8, 2022

Related Keywords

California ,United States ,South San Francisco ,Ukraine ,Kristin Yarema ,Atara Biotherapeutics Inc ,Company Senior Vice ,Technology Transfer Agreement ,Exchange Commission ,Company To Bayer ,Securities Exchange ,Program Transfer Agreement The Termination ,Company Quarterly Report On Form ,Material Definitive ,License Agreement ,Program Transfer Agreement ,Termination Agreement ,Supply Agreement ,Pharmacovigilance Agreement ,Equality Agreement ,Quarterly Report ,Charles River Laboratories ,Commercial Manufacturing Agreement ,Corporate Strategy ,Securities Exchange Act ,Securities Act ,Certain Officers ,Compensatory Arrangements ,Senior Vice President ,Chief Commercial Officer ,Executive Employment Agreement ,Page Interactive Data File ,Looking Statements This Current Report ,San Francisco ,Financial Condition ,Edgar Online ,Atara Biotherapeutics ,Nc Stock Exchange ,News ,Information ,Press Release ,Item ,Entry ,Into ,Material ,Efinitive ,Reviously ,N ,Bay ,Tara ,Eceived ,Written ,Notice ,F ,Termination ,Rom ,Player ,G Atra Us0465131078 ,